STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3301 by analyst upside · 2026-08-13
RVMD
Revolution Medicines, Inc.
Healthcare · Market Cap $44B · P/E 0x
ANALYST PRICE TARGET
+8.1%
implied upside to consensus target
Current Price $205.26
Consensus Target $221.81
Bull Target $291.0
Bear Target $151.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
16
Hold
1
Sell
0
52-Week Low $34.88
52-Week High $208.76
YTD Return +159.8%
FUNDAMENTALS
Market Cap $44B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-8.88
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $34.88
52-Week High $208.76
Current Price $205.26
Bear Target $151.0
Bull Target $291.0
● Now $205.26 ● Target $221.81
TRADING DATA
Avg Volume 2.6M
YTD Return +159.8%
Analyst Count 21
Consensus Buy
Upside to Target +8.1%
Last Updated 2026-08-13

ANALYST SUMMARY

Revolution Medicines, Inc. (RVMD) is currently trading at $205.26 with a Wall Street consensus price target of $221.81, implying potential upside of 8.1% over the next 12 months. 21 analysts currently cover RVMD, with a consensus rating of Buy - 95% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $291.0, while the most cautious has a target of $151.0.

RVMD operates in the Healthcare sector with a market capitalisation of $44B. The stock is up 159.8% year-to-date and is currently trading near the upper end of its 52-week range of $34.88 – $208.76.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RVMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group - Reiterated
Outperform → Outperform 2026-06-10 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-06-02 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-01 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-06-01 14% win rate (7 calls)
Bernstein ● Initiated
Market Perform 2026-05-22 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-07 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-05-07 62% win rate (8 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-05-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
24/30
Consensus clarity
16/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →